Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem cells in terms of technology and applications.
Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem cells in terms of technology and applications.
Shin Kawamata, MD, PhD, Director of the R&D Center for Cell Therapy at the FBRI (Kobe, Japan) stresses the importance of controlling the quality of iPSC banks at a very early stage, including CiRA cell lines, to meet safety guidelines at clinical stages.
Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies. Starting from a reflection on the differences in public funding strategies in Europe, North America, and Asia, he highlights the rationale behing the technological push in stem cell therapies in Asia.
Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner in several international VC funds. Given his strong expertise in stem cell therapy biotechs, we asked him about the key challenges that need to be addressed by the industry.
Involved in the acquitision of Bluerock Therapeutics by Bayer in 2019, as Investment Director, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies. We asked him about cell quality and current regulatory standards…
Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner in several international VC funds. Given its specific expertise in stem cell therapies, we asked him why funding rounds and IPOs in the field have skyrocketed in 2020.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, discusses the view according to which transplanting too much beta cells is not an issue in cell therapy.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, gives a quick overview of the limitations of pancreatic progenitor transplants.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, explains the rationale behind cell therapies for diabetes, and the specific issues related to the Type I and Type II forms.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, discusses the pro and cons of shielding stem-cell derived β-Cells with alginate, versus strategies aiming at reducing the immunogenicity of transplanted cells.
Albert Hwa explains why the Joslin’s CCTD launched an autologous cell therapy program, and discusses the promise of allogeneic cell therapies for Diabetes.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD), provides an overview of the cell therapy initiatives and current trials in the field of Diabetes, including ViaCyte, Vertex (Semma Therapeutics), Novo Nordisk, Lilly (Sigilon), Evotec (Sanofi)
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses the benefits of hypoxic conditions in iPS facilities.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses autologous iPS and HLA-matched embryonic stem cells.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, on the organoid format for next generation cell therapies.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, on gene-editing strategies for iPS-derived cell therapies.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses the industrial challenges related to cell therapies: manufacturing, safety testing, administration mode.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, presents the Oncopanel strategy to evaluate the genomic safety of clinical-grade iPS lines.